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Abstract 
AIM: The purpose of this meta-analysis was the assessment of the serum IL-6 levels in the renal transplant 
recipients compared to the healthy controls. 
MATERIAL AND METHODS: Four databases including PubMed, Web of Science, Scopus, and Cochrane Library 
were searched up to July 2018 without language restriction. The quality of studies was evaluated using the 
Newcastle-Ottawa scale (NOS). A continuous random-effects meta-analysis was used by RevMan 5.3 using the 
mean difference (MD) and 95% confidence intervals (CIs). Also, a regression model was done by Comprehensive 
Meta-Analysis version 2 (CMA v2). 
RESULTS: Out of 615 studies identified in the databases, 15 studies included and analysed in the meta-analysis. 
The studies were reported from 1994 to 2018. The meta-analysis included 1035 renal transplant recipients and 
682 healthy controls. The pooled MD of the serum IL-6 levels in the transplant recipients compared to the healthy 
controls was 3.25 pg/mL [95%CI: 2.17, 4.32; P < 0.00001; I2 = 98% (P < 0.00001)]. Meta-regression analysis 
showed that one of the reasons of heterogeneity is the year of publication (Correlation coefficient (r) = 0.208, p-
value = 0.00002). 
CONCLUSION: An elevated serum IL-6 level in the renal transplant recipients compared to the healthy controls 
showed that the serum level of this marker could be used for the evaluation of inflammation in ESRD patients 
undergoing renal transplantation. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Chronic kidney disease (CKD) is the usual 
name for various disorders impacting renal structure 
and functions [1]. The incidence of cardiovascular 
disease in patients of end-stage renal disease (ESRD) 
is 10–20-fold that in the general population [2]. Renal 
transplantation (RT) is the treatment of choice for 
ESRD patients [3], [4]. Acute rejection is a common 
complication after RT and is associated with reduced 
graft survival [5]. Cardiovascular and cerebrovascular 
diseases are the leading causes of death following 
renal transplantation [6], [7] that the main underlying 
reason is inflammation [7]. Inflammation is generally 
controlled by following changes in concentrations of 
C-reactive protein (CRP), cytokines, and chemokines 
[8]. Interleukin-6 (IL-6) is reportedly responsible for 
acute complications in patients with ESRD such as 
fever, headache, and hypotension [9]. This cytokine is 
also a reliable marker of disease severity and 
inflammatory organ injury in rheumatoid arthritis [10] 
and oral lichen planus [11]. Therefore, it has been 
found to act as both a pro-inflammatory and anti-
inflammatory cytokine [12]. Also, the serum IL-6 levels 
increase depending on the reduction of renal function 
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[13].  
The meta-analysis aimed to assess the serum 
IL-6 levels in the renal transplant recipients compared 
to the healthy controls. 
 
 
Material and Methods 
 
The meta-analysis created according to a 
guideline for the preferred reporting items for 
systematic review and meta-analysis (PRISMA) 
literature search [14]. 
The research protocol was supported by the 
Ethics Committee of Kermanshah University of 
Medical Sciences, Kermanshah, Iran (Ethical code: 
IR.KUMS.REC.1396.597). A comprehensive search 
was used with the databases of PubMed, Web of 
Science, Scopus, and Cochrane Library up to July 
2018. A combination of terms “kidney transplantation" 
or "renal transplantation" or "kidney transplant" or 
"renal transplant" and “serum” and "interleukin-6" or 
“IL-6” was used in the search without language 
restriction. The studies were selected for evaluation of 
the serum IL-6 levels in the renal transplant recipients 
compared with the healthy controls. The studies 
included in this meta-analysis had to: (I) use a case-
control design; (II) report the serum IL-6 levels in the 
renal transplant recipients (III) report the controls 
without renal transplantation and any systematic 
disease (the healthy controls). Before transplantation, 
the more renal transplant recipients were on renal 
replacement therapy (pretransplant dialysis) and had 
immunosuppressive treatment.  
One reviewer (M.S) searched the articles and 
then selected the relevant publications and other 
authors reviewed them independently. We applied a 
regular protocol and recording information for data 
extraction from each publication including the first 
author’s name, the year of publication, the country 
which the study was reported, number/the mean 
age/male (%) of the cases and healthy controls, 
immunosuppressive regimen, measured method of IL-
6 level, and transplantation evolution. 
The quality of studies was evaluated using the 
Newcastle-Ottawa scale (NOS)
 
[15],
 
in which the 
maximum total score is 9 for the case-control study. 
The quality evaluation was done by one author (M.S) 
for each study. 
To compare serum IL-6 levels in the renal 
transplant recipients compared with the healthy 
controls, a continuous random-effects meta-analysis 
was done by Review Manager 5.3 (RevMan 5.3, The 
Cochrane Collaboration, Oxford, United Kingdom) 
using the mean difference (MD) and 95% confidence 
intervals (CIs). Heterogeneity among studies was 
evaluated with the Q, and the I
2
 statistic and results 
were defined as heterogeneous for P < 0.10 or I
2 
> 
50% [16] and P-value (2-sided) < 0.05 was estimated 
statistically significant in the meta-analysis study. 
Also, the publication bias was estimated by funnel plot 
using Begg’s and Egger’s tests. The unit of 
measurement of IL-6 levels was pg/mL. The meta-
regression analysis is a technique used to evaluate 
heterogeneity between the studies. This statistical 
approach determines whether there is a significant 
association between the study period and the pooled 
MD of the serum IL-6 levels. A regression model by 
Comprehensive Meta-Analysis version 2 (CMA v2) 
was done with the p-value and regression coefficient 
(r) to evaluate the strength of this association.  
 
 
Results 
 
Out of 615 studies identified in the databases, 
after excluding duplicate studies, 344 studies were 
screened that 312 studies were excluded. Out of 32 
studies that their full-texts were assessed for eligibility, 
17 studies were removed with the reasons (Figure 1). 
At last, 15 studies included and analysed in the meta-
analysis.  
 
Figure 1: Flowchart of the study 
 
The features of 17 studies that have been 
included in the meta-analysis are shown in Table 1. 
The studies were reported from 1994 to 2018. Three 
studies [17], [18], [19] were reported from Poland, two 
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[7], [20] from Turkey, two [15], [16] from Iran, and also 
Canada, Germany, the USA, Argentina, Spain, 
Connecticut, India, and China (one study each) [6], 
[8], [21], [22], [23], [24], [25], [26]. The meta-analysis 
included 1035 renal transplant recipients and 682 
healthy controls. Six studies [3], [8], [20], [24], [25], 
[27] reported pretransplant dialysis in all or more 
recipients. Eight studies [6], [8], [17], [18], [19], [22], 
[25], [27] reported stable transplantation as inclusion 
criteria in the recipients and two other studies [23], 
[26] showed acute rejection and stable evolutions. 
The mean age, male percentage, immunosuppressive 
regimens, and measured method of IL-6 level are 
shown in Table 1.  
Table 1: Characteristics of the studies included in the meta-
analysis (n = 15) 
 Countr
y 
No. of 
Transplant 
recipients/
mean age, 
year/No. of 
males 
No. of 
healthy 
controls/ 
mean 
age, 
year/ 
No. of 
males 
Pretrans
plant 
dialysis 
in all or 
more 
recipient
s 
 
Immunosuppressiv
e regimen  
Measured Method of 
interleukin-6 level 
Transpl
antatio
n 
evoluti
on  
Nickerson, 
1994 [21] 
Canad
a 
38/46.1/24 
 
31/matc
hed/mat
ched 
- Azathioprine, 
Prednisone, and 
cyclosporine 
ELISA kits (R & D 
systems, Quantikine 
human IL-6 
immunoassay, 
Minneapolis, MN) 
- 
Waiser, 
1997 [22] 
Germ
any 
145/-/- 20/-/- - Cyclosporine and 
methylprednisolone  
 
ELISA kits (R&D 
Systems, Quantikine 
human IL-6 
immunoassay) 
Stable 
Preston, 
2002 [8] 
USA 10/-/- 10/-/- Yes - ELISA kits (MMP-2 and 
MMP-3, Amersham 
Life Science, 
Buckinghamshire, 
England; IL-6, 
Biosource 
International, Inc., 
Camarillo, Calif., USA) 
Stable 
Malan 
Borel, 
2003 [23] 
Argent
ina 
13 
rejection:11 
stable/-/- 
20/-/- - Prednisone, 
cyclosporine or 
FK506 
ELISA kits ( the 
Quantikine 
immunoassay (R & D 
Systems Inc., 
Minneapolis, USA) 
Acute 
rejectio
n vs. 
stable 
Lauzurica, 
2005 [24] 
Spain 178/53/117 40/-/- Yes Corticosteroids  
or azathioprine and 
Cyclosporine or 
tacrolimus  
An immunofluorimetric 
automatized method in 
Immulite-1 (DPC-
Dipesa) 
- 
Malyszko, 
2006 [17] 
Polan
d 
96/52.7/48 33/50.6/
- 
- Cyclosporine, 
prednisone, and 
azathioprine 
(high-sensitivity 
assays) 
from Bender 
MedSystem (Vienna, 
Austria) 
Stable 
Malyszko, 
2008 [18] 
Polan
d 
90/46.2/43 30/44.8/
14 
- Cyclosporine/tacroli
mus, 
azathioprine/mycop
henolate 
mofetil plus 
prednisone. 
kits from Bender 
MedSystems (Vienna, 
Austria) 
Stable 
Shaqman, 
2010 [25] 
Conne
cticut 
90/53/48 72/51/1
2 
Yes Prednisone, and 
cyclosporine 
ELISA kits (Diagnostic 
Products, Los Angeles, 
CA) 
Stable 
Malyszko, 
2013 [19] 
Polan
d 
62/44.3/35 24/51.6/
- 
- Calcineurin inhibitor 
in combination with 
mycophenolate 
mofetil and 
prednisone. 
Enzyme immunoassay 
(EIA) using a 
commercially available 
kits from Bachem (St. 
Helens, UK). 
Stable 
 
Sonkar, 
2013 [26] 
India 40 
rejection:50 
stable/32.3/
- 
90/30.4/
- 
- Cyclosporine, 
azathioprine, and 
prednisone. 
ELISA kits (Beckman 
Coulter Inc, Marseille, 
France) 
Acute 
rejectio
n vs. 
stable 
Xue, 2014 
[6] 
China 25/44.3/12 25/45.9/
15 
- Cyclosporine, 
mycophenolate 
mofetil, and 
prednisone. 
ELISA kits (Boster 
Biological Engineering 
(Huhan, China). 
Stable 
 
Colak, 
2015 [20] 
Turke
y 
45/40.7/24 36/42.1/
19 
Yes Calcineurin 
inhibitors, steroids 
and mycophenolate 
mofetil 
ELISA kits (Camarillo, 
CA, USA)  
- 
Avci Çiçek, 
2016 [7] 
Turke
y 
82/41.8/43 81/46.7/
- 
- - commercial kit 
(eBioscience, 
Austria) 
- 
Eskandari 
Naji, 2017 
[3] 
 Iran 30/48.5/18 30/50.4/
15 
Yes Cyclosporine, 
CellCept, and 
prednisolone  
ELISA (DIA source, 
Belgium, catalog 
number: KAP1261) 
- 
Argani, 
2018 [27] 
Iran 30/49/18 30/50/1
5 
Yes Prednisolone, 
calcineurin 
inhibitor, and 
CellCept 
ELISA kits (IBL 
International GmbH, 
Germany). 
Stable 
 
 
Figure 2 is shown the forest plot of random-
effects analysis that the pooled MD of the serum IL-6 
levels in the transplant recipients compared to the 
healthy controls was 3.25 pg/mL [95%CI: 2.17, 4.32; 
P < 0.00001; I
2 
= 98% (P < 0.00001)]. Therefore, the 
serum IL-6 level in the transplant recipients was 
significantly higher than the healthy controls. 
 
Figure 2: Forest plot of random-effects of serum interleukin-6 levels 
in the renal transplant recipients compared to the healthy controls. i: 
the renal transplant recipients with stable evolution, and ii: the renal 
transplant recipients with acute rejection evolution 
 
Table 2 shows the quality score for each 
study included in the meta-analysis. The mean score 
was 5.8 for all case-control studies. 
Table 2: Quality ratings for the studies included by Newcastle-
Ottawa quality assessment scale (n = 15) 
The first author, year Selection Comparability* Outcome Total score 
Nickerson, 1994 [21] 2 0 2 4 
Waiser, 1997 [22] 2 0 2 4 
Preston, 2002 [8] 2 0 2 4 
Malan Borel, 2003 [23] 4 1 2 7 
Lauzurica, 2005 [24] 3 0 2 5 
Malyszko, 2006 [17] 3 1 2 6 
Malyszko, 2008 [18] 3 2 2 7 
Shaqman, 2010 [25] 3 1 2 6 
Malyszko, 2013 [19] 2 0 2 4 
Sonkar, 2013 [26] 3 2 2 7 
Xue, 2014 [6] 3 2 2 7 
Colak, 2015 [20] 4 2 2 8 
Avci Çiçek, 2016 [7] 3 0 2 5 
Eskandari Naji, 2017 [3] 2 2 2 6 
Argani, 2018 [27] 3 2 2 7 
*One star if two groups matched via age and another star if two groups matched via sex or 
body mass index (BMI). 
 
Figure 3 shows the funnel plot of studies 
entered to the analysis. Egger’s test (p-value (2-tailed) 
= 0.042) reveal, but and Begg’s test (p-value (2-tailed) 
= 0.067) didn’t reveal a significant sign of publication 
bias between the involved studies. 
 
 
Figure 3: Funnel plot of random-effects of serum interleukin-6 levels 
in the transplant recipients compared to the healthy controls 
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Meta-regression analysis identified a 
significant statistical relationship between the pooled 
MD of serum IL-6 levels in the renal transplant 
recipients compared with the healthy controls and the 
year of publication. This means that one of the 
reasons for heterogeneity is the year of publication 
(Correlation coefficient (r) = 0.208, p-value = 
0.00002). Significant positive correlation showed that 
there was an increase in the MD of the serum IL-6 
with time (Figure 4). 
 
Figure 4: Meta-regression analysis the study period versus the 
mean difference of the serum IL-6 levels 
 
 
 
Discussion 
 
The elevated serum IL-6 levels in the renal 
transplant recipients compared to the healthy controls 
have been shown in this meta-analysis study. The 
Th1 cytokine pattern is generally related to the 
rejection of the transplantation; a Th2 cytokine pattern 
may lead to transplant tolerance and stable graft 
survival. [13]. Inflammation is the most important 
underlying mechanism in cardiovascular disease and 
other systemic diseases [1]. Increased IL-6 leads to 
chronic inflammatory conditions such as the synthesis 
of acute phase proteins like CRP, hypercoagulability 
and accelerated atherosclerosis. [7], [28], [29], [30], 
[31] that can cause to the loss of renal function [7]. 
Also, some mechanisms including volume overload 
and oxidative stress can cause the usual increase in 
inflammatory symptoms (including IL-6) [32].  
Serum levels of IL-6 increased significantly 
after renal transplantation [33]. The results received 
show an obvious relationship within the serum levels 
of IL-6 and graft rejection [23]. Levels of IL-6 have 
been greatly reduced in desirable evolution and raised 
with increasing renal failure. Therefore, the level of IL-
6 can be used as an indicator of graft evolution and as 
a prerequisite for proper evaluation of renal biopsy 
[23]. The changes in the serum levels of IL-6 in 
transplanted patients can lead to several factors that 
affect the production of cytokines. Also, IL-6 may act a 
function in the close correlation between the high 
incidence of inflammation, cardiovascular disease, 
and malnutrition in HD patients [34]. CRP elevation 
may only represent the end stage of substantial 
inflammation, and other inflammatory markers may be 
more sensitive indicators of early inflammation injury, 
almost in HD patients [8]. Therefore, levels of CRP 
can correlate with IL-6 levels [9]. Serum levels of IL-6 
in HD patients are significantly higher than in renal 
transplant recipients [20], [35]. The injury to the 
endothelium might trigger the release of IL-6 in renal 
transplant recipients [26]. This increase in IL-6 could 
be the result of increased activation of nuclear factor-
kappa B, which is an inducible transplantation factor 
necessary for the activation of multiple important 
inflammatory cytokine genes like to the IL-6 gene [36]. 
1) Pretransplant dialysis in the recipients. 2) Different 
immunosuppressive treatment in the recipients. 3) 
Differences in the measured method of IL-6 levels. 4) 
The sample size was small in some studies. 5) There 
was high heterogeneity in the analysis. 6) Low quality 
of more studies. Therefore, these limitations cause a 
bias between the studies.  
In conclusion, about the limitations, there was 
an elevated serum IL-6 level in the renal transplant 
recipients compared to the healthy controls. The 
results may indicate potential usefulness of the serum 
level of this marker as an indicator of immunologic risk 
and can be used for the evaluation of inflammation in 
ESRD patients undergoing renal transplantation. HRO 
and SG conceptualised this study, designed the 
methodology for data collection, collected and 
analysed the data, and wrote the manuscript. SVJ and 
MS extensively supported the development of the 
study concept, data analysis, and the writing, editing 
and finalising of the manuscript. All authors read and 
approved the final manuscript. 
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